stock Healthcare Drug Manufacturers - General

NVS

Novartis AG ADR

$160.68

29.73% · 1Y change

Trend

Strong Bullish

+29.73%

P/E

30.69

Div yield

2.9%

Mkt cap

$303.67B

Beta

0.47

Trend read · Strong Bullish

How NVS performs — and a starting point for your own research.

Price & mood

Market Mood

PriceEMA 11/31/153 (trend)Range 1Y $122.86 – $170.46

Idea: EMA

1Y Return

+20.8%

Sharpe 3Y

0.58

Market comparison

vs sector & industry

NVS

1Y performance

+29.73%

Healthcare

Sector · 1Y

Drug Manufacturers - General

Industry · 1Y

Past performance. The future stays open.

Wall Street coverage

third-party context

Wall Street coverage

$154.80median target· current $160.68 (-3.7%)12 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

49 articles · sorted by date

Page 1 of 3 · 49 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close

P/E ratio30.69Forward 16.16

EPS (TTM)$5.24-68.8% YoY

Profit margin17.5%HEALTHCARE

Market cap$303.67BMega cap

Valuation

Forward P/E: 16.16
PEG ratio: 3.85
P/B: 8.17
P/S (TTM): 5.29
EV/EBITDA: 15.52

Profitability & growth

ROE (TTM): 24.3%
Operating margin: 34.3%
Revenue growth YoY: 4.7%
Dividend yield: 2.9%
Beta: 0.47

Last earnings

Oct 27, 2026 · Estimate $2.25 · Reported $2.46

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Novartis AG ADR

Company profile

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: LICHTSTRASSE 35, BASEL, SWITZERLAND
Fiscal year end: December
Latest quarter: Sep 30, 2026

Market cap$303.67B

Shares outstanding$1.89B

52W high$165.43

52W low$119.23

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

NVS

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

Novartis stock faces mixed signals as guidance improves

Novartis AG downgraded by Deutsche Bank

Aktien von Roche, Novartis und Co.: Pharma-Zahlungen in der Schweiz gehen zurück

Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside

Morgan Stanley Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $163

Novartis earnings analysis: questions answered and next catalysts

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis

Novartis reports Q3 core EPS $2.46 vs. $2.25 last year

Novartis raises profit outlook after strong Q3 sales growth; shares rise

Form 6-K NOVARTIS AG For: Sep 30

Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment

Novartis AG's Q3 revenue rose 4% year-on-year, while impairments in long-term pipeline assets weighed on net profit.

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis AG Estimates – BX:NOT

Novartis AG Lobbying Profile, 2004

Earnings Preview: Novartis AG to Report Financial Results on October 27

Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)

Fundamentals

Valuation

Profitability & growth

About Novartis AG ADR

Classification

Company profile

NVS

Price & mood

Market comparison

NVS Market Analysis

NVS

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

Novartis stock faces mixed signals as guidance improves

Novartis AG downgraded by Deutsche Bank

Aktien von Roche, Novartis und Co.: Pharma-Zahlungen in der Schweiz gehen zurück

Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside

Morgan Stanley Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $163

Novartis earnings analysis: questions answered and next catalysts

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis

Novartis reports Q3 core EPS $2.46 vs. $2.25 last year

Novartis raises profit outlook after strong Q3 sales growth; shares rise

Form 6-K NOVARTIS AG For: Sep 30

Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment

Novartis AG's Q3 revenue rose 4% year-on-year, while impairments in long-term pipeline assets weighed on net profit.

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis AG Estimates – BX:NOT

Novartis AG Lobbying Profile, 2004

Earnings Preview: Novartis AG to Report Financial Results on October 27

Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)

Fundamentals

Valuation

Profitability & growth

About Novartis AG ADR

Classification

Company profile

NVS

Price & mood

Market comparison